Ross Margulies, J.D., M.P.H., a partner at the Foley Hoag law firm, says there is broad agreement on transparency provisions and a ban on spread pricing in Medicaid.
After years of federal inaction, momentum started to build last year for legislation would impose new rules on the pharmacy benefit manager (PBM) industry. Many observers expect a bill to pass this year, during this Congress, although perhaps not until the lame-duck session after the Nov. 5 election. But what that bill will include is still far from certain, with various interest groups and ideas jostling for position and influence over what does and does not get included.
Ross Margulies, J.D., M.P.H., a partner in the Foley Hoag law firm, spoke about the PBM legislation today at the 2024 Annual Meeting of the Academy of Managed Care Pharmacy, which is being held in the Ernest N. Morial Convention Center in New Orleans.Margulies spoke to Managed Healthcare Executive in a recorded video call prior to the meeting. Foley Hoag, which is headquartered in Boston, has had many “drug supply chain actors” as clients and has represented the major PBMs, according to Margulies.
Margulies said in his interview with MHE that any PBM legislation that the senators and representatives agree upon is likely to include PBM pricing and fee transparency rules that will require the PBMs to share more detailed information with payers. Similar transparency requirements might be applied to Medicare Part D sponsors. He also said that after the transparency rules, the next most likely ingredient of a PBM bill would be a ban on spread pricing by PBMs serving Medicaid programs.
340B Program Is Driving Up Costs and Needs Urgent Reform | AMCP Annual 2025
April 7th 2025At the 2025 AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential reforms in a conversation with Managed Healthcare Executive.
Read More
Exploring the Wide World of GLP-1s | AMCP Annual 2025
April 3rd 2025Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their effects on various other conditions, such as sleep apnea, substance use disorder and Alzheimer’s disease, according to panelists participating in a keynote session of the Academy of Managed Care Pharmacy annual meeting today in Houston.
Read More
2024-2025 Pharmacy Trends Include Improved Drug Shortages, More Pharmacy Closures | AMCP Annual 2025
April 2nd 2025Scott Biggs and Douglas M. Long of IQVIA delivered a keynote on 2024-2025 healthcare and pharmaceutical trends, highlighting drug shortages, pharmacy closures, and the United States dependence on imported pharmaceuticals.
Read More